LDC000067

N.º de catálogoS7461 Lote:S746102

Imprimir

Datos técnicos

Fórmula

C18H18N4O3S
Peso molecular 370.43 Número CAS 1073485-20-7
Solubilidad (25°C)* In vitro DMSO 74 mg/mL (199.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Agregue los solventes al producto individualmente y en orden.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml significa ligeramente soluble o insoluble.
* Tenga en cuenta que Selleck prueba la solubilidad de todos los compuestos internamente, y la solubilidad real puede diferir ligeramente de los valores publicados. Esto es normal y se debe a ligeras variaciones entre lotes.
* Envío a temperatura ambiente (Las pruebas de estabilidad demuestran que este producto se puede enviar sin medidas de refrigeración.)

Preparación de soluciones madre

Actividad biológica

Descripción LDC000067 (LDC067) es un inhibidor de CDK9 altamente selectivo con una IC50 de 44 nM, con una selectividad 55/125/210/ >227/ >227 veces mayor sobre CDK2/1/4/6/7.
Objetivos
CDK9
(Cell-free assay)		 CDK2
(Cell-free assay)
44 nM 2.441 μM
In vitro LDC000067 reduce la Ser2-P, induce la activación de p53 y conduce a la apoptosis en mESC. Además, LDC067 también inhibe de forma dosis-dependiente la síntesis de novo de ARN dependiente de P-TEFb de genes celulares.
Características Inhibidor selectivo de CDK9.

Protocolo (de referencia)

Referencias

  • https://pubmed.ncbi.nlm.nih.gov/24102143/

Validación de productos por parte del cliente

<p>Inhibition of CDK9 leads to a decrease in RNApol II activity and repetitive element expression. HEK293T cells were treated with DMSO control and the indicated amounts of LDC000067, a CDK9 inhibitor, for a total of 3 h. (A) Immunoblots showing the levels of phosphorylated RNApol II largest subunit (pRPB1), total RPB1 and GAPDH, in response to different doses of CDK9 inhibitor. (B) Quantification of immunoblots from 2 independent experiments in which each condition was performed in duplicates, and in which pRPB1 and total RPB1 protein levels were normalized to GAPDH or as pRPB1/Total RPB1 ratio. (C, D) qRT-PCR analyses show a significant response to CDK9 inhibition of repetitive elements belonging to the LTR (C) and SINE (D) classes. Statistical analyses were performed to compare all groups using a One-way ANOVA followed by Bonforreoni’s multiple comparison test, *P < 0.05, **P < 0.01, #P < 0.0001.</p>

, , Hum Mol Genet, 2017, 26(17):3421-3431

(B) Effects of siRNA-mediated depletion of CDK7, CDK9, or CDK7 and CDK9 on UKF-NB-3 and UKF-NB-3<sup>r</sup>SNS-032<sup>300nM</sup> cell viability as determined by MTT assay 72 h post-transfection. Non-targeting

Datos de [ , , Oncotarget, 2016, 7(36):58051-58064 ]

Inhibition of JQ1 enhancement effect on Ad2 infection by CDK9 inhibitor. A549 cells were infected with Ad2 in the absence or presence of 300 nM JQ1. For inhibition, LDC00067 was added simultaneously. Viral protein synthesis or virion production was detected at 24 and 36 h PI, respectively. The experiments were performed 2 times independently. Data represent mean ± SD of triplicate samples. *p < 0.05, **p < 0.01.

Datos de [ , , Sci Rep, 2018, 8(1):11554 ]

Western blotting after 24h of LDC000067 treatment, showing the expression of CDK9, RNA Pol II,phosphorylation of RNA Pol II (Ser2 and Ser5), anti-apoptotic proteins Mcl-1 and Survivin, and apoptotic-related protein Bax in (D)SYO-1 and (E) Fuji synovial sarcoma cells. The data are mean SD of the experiment carried out in triplicate.

Datos de [ , , J Orthop Res, 2018, doi:10.1002/jor.24189 ]

Sellecks LDC000067 Ha sido citado por 43 Publicaciones

Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer [ Cell Rep Med, 2025, S2666-3791(25)00231-9] PubMed: 40449480
Inherited blood cancer predisposition through altered transcription elongation [ Cell, 2024, 187(3):642-658.e19] PubMed: 38218188
Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers [ Nucleic Acids Research, 2023, 4341–4362] PubMed: None
Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers [ Nucleic Acids Res, 2023, gkad172] PubMed: 36928661
Aberrant accumulation of Kras-dependent pervasive transcripts during tumor progression renders cancer cells dependent on PAF1 expression [ Cell Rep, 2023, 42(8):112979] PubMed: 37572321
The PAF1 complex promotes 3' processing of pervasive transcripts [ Cell Rep, 2022, 38(11):110519] PubMed: 35294889
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer [ Breast Cancer Res, 2022, 24(1):41] PubMed: 35715861
CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma [ Autophagy, 2021, 1-19] PubMed: 34890308
Probing the signaling requirements for naive human pluripotency by high-throughput chemical screening [ Cell Rep, 2021, 35(11):109233] PubMed: 34133938
Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling [ Acta Pharmacol Sin, 2021, 10.1038/s41401-021-00708-2] PubMed: 34188177

POLÍTICA DE DEVOLUCIÓN
La Política de Devolución Incondicional de Selleck Chemical garantiza una experiencia de compra en línea fluida para nuestros clientes. Si no está satisfecho con su compra de alguna manera, puede devolver cualquier artículo(s) dentro de los 7 días posteriores a su recepción. En caso de problemas de calidad del producto, ya sean problemas relacionados con el protocolo o con el producto, puede devolver cualquier artículo(s) dentro de los 365 días a partir de la fecha de compra original. Siga las instrucciones a continuación al devolver productos.

ENVÍO Y ALMACENAMIENTO
Los productos Selleck se transportan a temperatura ambiente. Si recibe el producto a temperatura ambiente, tenga la seguridad de que el Departamento de Inspección de Calidad de Selleck ha realizado experimentos para verificar que la colocación a temperatura normal durante un mes no afectará la actividad biológica de los productos en polvo. Después de la recogida, guarde el producto de acuerdo con los requisitos descritos en la hoja de datos. La mayoría de los productos Selleck son estables en las condiciones recomendadas.

NO PARA USO HUMANO, DIAGNÓSTICO VETERINARIO O TERAPÉUTICO.